Nick Powell, PharmD
Assistant Research Professor of Medicine
- Phone
- (317) 274-2758
- Address
-
R2 402
MDEP
IN
Indianapolis, IN - PubMed:
- CV:
- Download CV
Bio
My current appointment in the Division of Clinical Pharmacology is the culmination of over 10 years of research experience in pharmacy practice, academia, and the pharmaceutical industry. My background in insulin manufacturing at Eli Lilly and Company and my training in pharmacogenomics and computational omics-level analyses provide a unique combination of skills that I use to conduct pharmacogenomics research. Pharmacogenomics research is on the precipice of moving from the current paradigm of monogenic predictors to polygenic predictors of drug response and I aim to advance the field to improve our understanding of the inter-individual variability in drug response.Key Publications
- Powell NR, Shugg T, Ly RC, Albany C, Radovich M, Schneider BP, Skaar TC. Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report. Frontiers in Oncology. 2022 January 31; 11. Available from: https://www.frontiersin.org/article/10.3389/fonc.2021.809527 DOI: 10.3389/fonc.2021.809527
- Powell NR, Zhao H, Ipe J, Liu Y, Skaar TC. Mapping the miRNA-mRNA Interactome in Human Hepatocytes and Identification of Functional mirSNPs in Pharmacogenes. Clin Pharmacol Ther. 2021 Oct;110(4):1106-1118. PubMed PMID: 34314509.
- For full list: https://orcid.org/0000-0003-4572-0733
| Year | Degree | Institution |
|---|---|---|
| 2013 | PharmD | Butler University |
One of the biggest inefficiencies in healthcare is the one-size-fits-all disease treatment model, and it’s my long-term career goal to address this problem by developing and demonstrating individualized treatment models that reduce toxicity and increase efficacy. To this end, my overall research objective is to investigate monogenic, polygenic, and non-genetic predictors of drug response that can be used clinically to tailor drug treatment decisions. My research program utilizes (1) secondary retrospective analysis of large clinical trials and real world data to develop and validate predictive models of drug response, (2) in-vitro assays to characterize the function of variants in pharmacogenes and variability in expression of pharmacogenes, and (3) prospective clinical trials to establish the clinical utility of genetic or non-genetic drug response predictors.
My clinical experiences in both inpatient and retail pharmacy provide me a valuable perspective to work towards implementing predictive models as biomarkers of drug response.
Powell NR; Liang T; Ipe J; Cao S; Skaar TC; Desta Z; Qian HR; Ebert PJ; Chen Y; Thomas MK; Chalasani N; Nature communications 2023 Mar 17
Geck RC; Powell NR; Dunham MJ; American journal of human genetics 2023 Jan 20
Powell NR; Silvola RM; Howard JS; Badve S; Skaar TC; Ipe J; Cancer reports (Hoboken, N.J.) 2022 Jul 30
Powell NR; Shugg T; Ly RC; Albany C; Radovich M; Schneider BP; Skaar TC; Frontiers in oncology 2022 Jan 31
Shugg T; Powell NR; Marroum PJ; Skaar TC; Younis IR; Clinical pharmacology and therapeutics 2022 Aug 26
Powell NR; Zhao H; Ipe J; Liu Y; Skaar TC; Clinical pharmacology and therapeutics 2021 Aug 13
Smith LM; Bhattacharya D; Williams DJ; Dixon I; Powell NR; Erkina TY; Erkine AM; Cell stress & chaperones 2015 May 24